1048 AB821 is a CD8+ T cell selective IL-21 with enhanced bioavailability that reduces CD8+ T cell exhaustion to induce potent antitumor activity

• Ivana Djuretic,
• Yik Andy Yeung,
• Renee Greer,
• Arisa Paul,
• Jeffrey Houser,
• Audrey Hollingsworth,
• Wei Wei Prior,
• Manu Kumar,
• Ruth Lan

Affiliations

Ivana Djuretic

Asher Biotherapeutics, Inc, South San Francisco, CA, USA

Yik Andy Yeung

Asher Biotherapeutics, Inc, South San Francisco, CA, USA

Renee Greer

Asher Biotherapeutics, Inc, South San Francisco, CA, USA

Arisa Paul

Asher Biotherapeutics, Inc, South San Francisco, CA, USA

Jeffrey Houser

Asher Biotherapeutics, Inc, South San Francisco, CA, USA

Audrey Hollingsworth

Asher Biotherapeutics, Inc, South San Francisco, CA, USA

Wei Wei Prior

Asher Biotherapeutics, Inc, South San Francisco, CA, USA

Manu Kumar

Asher Biotherapeutics, Inc, South San Francisco, CA, USA

Ruth Lan

Asher Biotherapeutics, Inc, South San Francisco, CA, USA